New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Largest Tocomin SupraBio study shows brain benefits

Largest Tocomin SupraBio study shows brain benefits
Groundbreaking, largest-ever tocotrienols human clinical study, published in Stroke, shows that natural full-spectrum palm mixed tocotrienol complex protects brains.

Carotech, the largest and only GMP-certified tocotrienol producer in world, announces a groundbreaking, largest ever tocotrienols human clinical study results for neuroprotection. Published in the American Heart Association’s peer-reviewed journal Stroke, this randomized, double-blind, placebo-controlled clinical trial successfully demonstrated that natural full-spectrum palm mixed tocotrienol complex (Tocomin SupraBio®) is effective in attenuating the progression of white matter lesions (WMLs) in humans.

Brain WMLs are closely related to vascular events of the brain and are indications of fragile brain vascular network, and an independent prognostic measure of future stroke risk.

“Considerable evidence exists that palm tocotrienol complex protects stroke-induced injuries in vitro and in animal studies," said WH Leong, vice president of Carotech Inc. "This study clearly demonstrates neuroprotective effect of Tocomin SupraBio supplementation in human, as reflected by significant decrease of white matter lesion volume.”

This clinical trial evaluated the neuroprotective properties of a patented and bioenhanced palm tocotrienol complex, Tocovid SupraBio (Carotech Inc.) by measuring white matter changes in the brain using magnetic resonance imaging (MRI) at baseline, one year and two years of supplementation.

Using white matter lesions as arteriosclerotic model of small blood vessels in the brain, 121 volunteers aged 35 and above with cardiovascular risk factors and MRI-confirmed WMLs were randomized to receive 200 mg Tocovid SupraBio softgels or placebo twice daily for two years.

At two years of supplementation, the mean WML volume of the placebo group increased whereas those who received Tocovid Suprabio supplementation remained unchanged. The principal researcher, Prof KH Yuen concluded that supplementation with Tocomin SupraBio attenuates the progression of white matter lesions.

“The long awaited results of this clinical trial are finally published. We are extremely excited and proud of this significant scientific breakthrough of Tocomin SupraBio that provides conclusive evidence that this patented & bioenhanced full spectrum palm tocotrienol complex supports brain health in human,” said Leong.

Carotech has recently received Non-GMO Project Verification Seal for Tocomin SupraBio.



Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.